- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 09.10. | Pharmala Biotech Holdings Inc: Pharmala signs LaNeo distribution deal with Rua | 1 | Stockwatch | ||
| 22.09. | PharmAla Biotech setzt auf zweigleisige Strategie aus MDMA-Produktion und Wirkstoffentwicklung | - | Investing.com Deutsch | ||
| 18.09. | Pharmala Biotech Holdings Inc: Pharmala changes auditor to Davidson & Company | 1 | Stockwatch | ||
| 17.09. | PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill | 346 | GlobeNewswire (Europe) | TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 01.09. | XFRA NEW INSTRUMENTS AVAILABLE ON 01.09.2026 | 246 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.09.2026
Aktien
1 VGG863021256 SWVL Holdings Corp.
2... ► Artikel lesen | |
| 21.08. | Pharmala Biotech Holdings Inc: Pharmala gains U.S. patent, cancels APA-01 licence | 2 | Stockwatch | ||
| 21.08. | PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner | 693 | GlobeNewswire (Europe) | U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised... ► Artikel lesen | |
| 30.07. | Pharmala Biotech Holdings Inc: Pharmala Biotech loses $499,759 in fiscal Q3 | 1 | Stockwatch | ||
| 30.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements and AGM Update | 345 | GlobeNewswire (Europe) | TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 21.07. | Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug | 1 | FierceBiotech | ||
| 21.07. | Pharmala Biotech Holdings Inc: Pharmala licenses U.S. rights to ALA-002 to Jupiter | 1 | Stockwatch | ||
| 21.07. | PharmAla licenses ALA-002 drug to Jupiter for US market | 2 | Investing.com | ||
| 21.07. | PharmAla vergibt US-Lizenz für Wirkstoffkandidat ALA-002 an Jupiter | 1 | Investing.com Deutsch | ||
| 21.07. | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | 486 | GlobeNewswire (Europe) | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 07.07. | Pharmala Biotech Holdings Inc: Pharmala completes ALA-002 GMP drug substance run | 1 | Stockwatch | ||
| 06.07. | PharmAla Biotech: PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset | 208 | GlobeNewswire (Europe) | TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and... ► Artikel lesen | |
| 20.05. | Pharmala Biotech Holdings Inc: Pharmala signs U.S. ALA-002 licensing term sheet | 3 | Stockwatch | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 822 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | Pharmala Biotech Holdings Inc: Pharmala signs definitive agreement to form SPV Restora | 1 | Stockwatch |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,830 | +3,84 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 83,17 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,310 | -0,20 % | Guggenheim raises Rapport Therapeutics price target to $70 on trial data | ||
| PRAXIS PRECISION MEDICINES | 264,61 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,250 | 0,00 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| DISC MEDICINE | 79,45 | -0,04 % | Disc Medicine prices $450 million stock offering at $75/share | ||
| ARCUTIS BIOTHERAPEUTICS | 32,810 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 16,095 | +0,03 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,130 | +0,11 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| MAZE THERAPEUTICS | 32,450 | 0,00 % | Canaccord stuft Maze Therapeutics mit "Buy" ein - Nierentherapien bieten hohes Kurspotenzial | ||
| ABSCI | 9,070 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| VERADERMICS | 127,66 | +0,34 % | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| RECURSION PHARMACEUTICALS | 3,665 | +0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| EDGEWISE THERAPEUTICS | 39,730 | -0,05 % | William Blair initiates Edgewise Therapeutics stock with outperform rating | ||
| IMMUNOME | 17,920 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,103 Euro und damit +8,42 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.